Artelo Biosciences (NASDAQ:ARTL) Rating Reiterated by HC Wainwright

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 284.62% from the stock’s current price.

Artelo Biosciences Trading Up 2.8 %

NASDAQ ARTL opened at $1.30 on Wednesday. The firm has a market capitalization of $4.20 million, a PE ratio of -0.41 and a beta of 1.43. The business’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.41. Artelo Biosciences has a 12 month low of $1.15 and a 12 month high of $2.98.

Artelo Biosciences (NASDAQ:ARTL) last released its earnings results on Monday, May 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.27. As a group, analysts forecast that Artelo Biosciences will post -2.09 earnings per share for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.